Biological Variability of C-Reactive Protein and Specific Canine Pancreatic Lipase Immunoreactivity in Apparently Healthy Dogs

Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Oregon State University, Corvallis, OR 97330, USA.
Journal of Veterinary Internal Medicine (Impact Factor: 2.22). 05/2011; 25(4):825-30. DOI: 10.1111/j.1939-1676.2011.0729.x
Source: PubMed

ABSTRACT C-reactive protein (CRP) and specific canine pancreatic lipase immunoreactivity (Spec cPL) are biomarkers of generalized or nonspecific inflammation and pancreatic inflammation in dogs, respectively. The extent of inter- and intraindividual variation over time of these analytes is not well defined in dogs. The minimal critical difference for sequential determinations of these markers (ie, the smallest change necessary to represent physiological change rather than biological variation), has not been defined.
To determine the inter- and intraindividual variability (CV(G) and CV(I) ) and minimal critical difference for sequential determinations of serum CRP and Spec cPL concentrations in apparently healthy dogs.
Eleven apparently healthy dogs owned by staff or students at a veterinary teaching hospital.
Blood was collected repeatedly at varying intervals over 12 weeks. CRP and Spec cPL concentrations were determined with commercially available assays. Indices of inter-, intraindividual, and assay variability and 1-sided minimal critical differences for sequential concentrations were calculated.
For CRP, CV(G) was 90.8%, CV(I) was 115.5%, and the analytical variability (CV(A) ) was 6.3%; the index of individuality was 0.74, and 1-sided critical difference was 269.9%. For Spec cPL, CV(G) = 49.48%, CV(I) = 193.8%, CV(A) = 8.4%, index of individuality = 0.24, and 1-sided critical difference was 452.6%.
A population-based reference range is appropriate for Spec cPL, but questionable for CRP in dogs. Large changes in serial measurements of Spec cPL are necessary to infer clinical importance, more modest changes in CRP are likely to be meaningful.

Download full-text


Available from: Craig G Ruaux, Oct 07, 2014
1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: S100A12 (calgranulin C) is a Ca(2+)-binding protein that has been proposed to play a central role in both innate and acquired immune responses. In humans, S100A12 has been reported to be increased in serum and/or plasma in patients with various inflammatory disorders, and this protein has been suggested to be a sensitive and specific marker for inflammatory bowel disease (IBD). An immunoassay for S100A12 is currently available for use in humans, but antibodies against the human protein do not cross-react with canine S100A12 (cS100A12). Both sensitive and specific markers for canine patients with systemic or localized inflammatory diseases are currently lacking, thus the aim of this study was to develop and analytically validate a radioimmunoassay (RIA) for the quantification of cS100A12 in serum and fecal specimens and to determine the biological variation of cS100A12 in serum from healthy dogs. A competitive liquid-phase RIA was developed and analytically validated by determining assay working range, dilutional parallelism, spiking recovery, and intra- and inter-assay variability. Reference intervals for serum and fecal concentrations of cS100A12 were established from 124 and 65 healthy dogs, respectively, and components of variation for serum cS100A12 were determined from 11 dogs over 2.6 months. The working range of the assay was 0.6-432.7 μg/L. No cross-reactivity was observed with the cS100A8/A9 protein complex, the closest structural analogues available. Observed-to-expected ratios (O/E) for the serial dilution of serum and fecal extracts ranged from 97.2 to 146.8% and from 75.3 to 129.8%, respectively. O/E for spiking recovery for serum and fecal extracts ranged from 87.8 to 130.4% and from 84.8 to 143.8%, respectively. Coefficients of variation (CV) for intra- and inter-assay variability for sera were ≤ 8.1% and ≤ 7.8%, respectively, and were ≤ 7.8% and ≤ 8.7%, respectively, for fecal extracts. Reference intervals for serum and fecal cS100A12 were 33.2-225.1 μg/L and <24-745 ng/g, respectively. For biological variability testing, analytical, intra-individual, inter-individual, and total CV were 5.7, 29.2, 31.2, and 66.0%, respectively, yielding an index of individuality of 0.95 and a minimum critical difference (p<0.05) for sequential values of 84.9%. The RIA for cS100A12 measurement described here is analytically sensitive and specific, linear, accurate, precise, and reproducible, and will facilitate further research into the clinical utility of quantifying serum and fecal cS100A12 in canine patients with inflammatory diseases. Moderate changes in serum cS100A12 concentrations may be clinically relevant; however, the use of a population-based reference interval may require caution.
    Veterinary Immunology and Immunopathology 12/2011; 144(3-4):200-9. DOI:10.1016/j.vetimm.2011.09.011 · 1.75 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Measurement of C-reactive protein (CRP) is used for diagnosing and monitoring systemic inflammatory disease in canine patients. An automated human immunoturbidimetric assay has been validated for measuring canine CRP, but cross-reactivity with canine CRP is unpredictable.Objective The purpose of the study was to validate a new automated canine-specific immunoturbidimetric CRP method (Gentian cCRP).Methods Studies of imprecision, accuracy, prozone effect, interference, limit of quantification, and stability under different storage conditions were performed. The new method was compared with a human CRP assay previously validated for canine CRP determination. Samples from 40 healthy dogs were analyzed to establish a reference interval.ResultsTotal imprecision was < 2.4% for 4 tested serum pools analyzed twice daily over 10 days. The method was linear under dilution, and no prozone effect was detected at a concentration of 1200 mg/L. Recovery after spiking serum with purified canine CRP at 2 different concentrations was 123% and 116%, respectively. No interference from hemoglobin or triglycerides (10 g/L) was detected. CRP was stable for 14 days at 4°C and 22°C. In the method comparison study, there was good agreement between the validated human CRP assay and the new canine-specific assay. Healthy dogs had CRP concentrations that were less than the limit of quantification of the Gentian cCRP method (6.8 mg/L).Conclusions The new canine-specific immunoturbidimetric CRP assay is a reliable and rapid method for measuring canine CRP, suitable for clinical use due to the option for an automated assay.
    Veterinary Clinical Pathology 05/2014; 43(2). DOI:10.1111/vcp.12150 · 1.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: A chronic loss of canine α1 -proteinase inhibitor (cα1 -PI) into the gastrointestinal (GI) tract could change the systemic proteinase-proteinase inhibitor balance. Serum cα1 -PI concentrations have not been studied in dogs with well-defined GI diseases. OBJECTIVES: To further evaluate serum cα1 -PI concentrations in dogs with GI diseases, the objectives of this study were to (1) analytically validate a previously developed fecal cα1 -PI immunoassay to determine serum concentrations, (2) determine a population-based reference interval (RI) and assess the clinical utility, (3) determine stability of serum cα1 -PI, (4) determine the intra-individual variation in healthy dogs, and (5) determine the clinically relevant magnitude of change of serum cα1 -PI. METHODS: Prestudy validation of the (125) I-cα1 -PI immunoassay included linearity, spiking recovery, and intra- and inter-assay precision. A RI was calculated with samples of healthy dogs. Stability at -20°C was tested on 36 samples. Intra-individual variation was assessed using samples collected from 11 healthy dogs over a 12-week period. RESULTS: The cα1 -PI radioimmunoassay (RIA) was linear, accurate, precise, and reproducible. Serum cα1 -PI decreased by 11% after one year at -20°C. Analytical, intra-individual, inter-individual, and total variation were 6.4, 9.9, 9.0, and 25.3%, respectively. The RI for serum cα1 -PI was 732-1802 mg/L (n = 87); there were no differences between sex and age groups. The index of individuality was 1.31. As analytical variation was > ½ inter-individual variation, the minimum critical difference was not determined. CONCLUSIONS: The results of this study provide the basis for further evaluating serum cα1 -PI in dogs with GI disease. Using a population-based RI for serum cα1 -PI appears to be appropriate.
    Veterinary Clinical Pathology 04/2013; 42(2). DOI:10.1111/vcp.12039 · 1.21 Impact Factor